A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate ISH0688 Subcutaneous Injection
Latest Information Update: 09 Apr 2026
At a glance
- Drugs ISH 0688 (Primary)
- Indications Hyperlipidaemia; Hypertriglyceridaemia
- Focus Adverse reactions; First in man
- Sponsors SUNHO (China) BioPharmaceutical
Most Recent Events
- 09 Apr 2026 New trial record